Literature DB >> 9793760

Insulin degradation: progress and potential.

W C Duckworth1, R G Bennett, F G Hamel.   

Abstract

Insulin degradation is a regulated process that plays a role in controlling insulin action by removing and inactivating the hormone. Abnormalities in insulin clearance and degradation are present in various pathological conditions including type 2 diabetes and obesity and may be important in producing clinical problems. The uptake, processing, and degradation of insulin by cells is a complex process with multiple intracellular pathways. Most evidence supports IDE as the primary degradative mechanism, but other systems (PDI, lysosomes, and other enzymes) undoubtedly contribute to insulin metabolism. Recent studies support a multifunctional role for IDE, as an intracellular binding, regulatory, and degradative protein. IDE increases proteasome and steroid hormone receptor activity, and this activation is reversed by insulin. This raises the possibility of a direct intracellular interaction of insulin with IDE that could modulate protein and fat metabolism. The recent findings would place intracellular insulin-IDE interaction into the insulin signal transduction pathway for mediating the intermediate effects of insulin on fat and protein turnover.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9793760     DOI: 10.1210/edrv.19.5.0349

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  256 in total

1.  Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization.

Authors:  V Chesneau; K Vekrellis; M R Rosner; D J Selkoe
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

2.  Disorders of glucose metabolism: post mortem analyses in forensic cases--part II.

Authors:  Frank Musshoff; Cornelius Hess; Burkhard Madea
Journal:  Int J Legal Med       Date:  2010-10-07       Impact factor: 2.686

Review 3.  Hemopressin and other bioactive peptides from cytosolic proteins: are these non-classical neuropeptides?

Authors:  Julia S Gelman; Lloyd D Fricker
Journal:  AAPS J       Date:  2010-04-10       Impact factor: 4.009

Review 4.  Hepatic Insulin Clearance: Mechanism and Physiology.

Authors:  Sonia M Najjar; Germán Perdomo
Journal:  Physiology (Bethesda)       Date:  2019-05-01

5.  Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?

Authors:  Felix Kulozik; Christoph Hasslacher
Journal:  Ther Adv Endocrinol Metab       Date:  2013-08       Impact factor: 3.565

6.  Autoimmune-mediated glucose intolerance in a mouse model of systemic lupus erythematosus.

Authors:  Curtis L Gabriel; Patricia B Smith; Yanice V Mendez-Fernandez; Ashley J Wilhelm; Audrey Musi Ye; Amy S Major
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-10-02       Impact factor: 4.310

7.  Potential efficacy of Lactobacillus casei IBRC_M10711 on expression and activity of insulin degrading enzyme but not insulin degradation.

Authors:  Nadia Neyazi; Taiebeh Mohammadi Farsani; Zahra Nouri; Mohammad Hossein Ghahremani; Mohammad Reza Khorramizadeh; Roksana Tajerian; Elahe Motevaseli
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-08-29       Impact factor: 2.416

8.  Clinical correlates of insulin sensitivity and its association with mortality among men with CKD stages 3 and 4.

Authors:  Hong Xu; Xiaoyan Huang; Johan Arnlöv; Tommy Cederholm; Peter Stenvinkel; Bengt Lindholm; Ulf Risérus; Juan Jesús Carrero
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-16       Impact factor: 8.237

9.  Systemically modeling the dynamics of plasma insulin in subcutaneous injection of insulin analogues for type 1 diabetes.

Authors:  Jiaxu Li; Yang Kuang
Journal:  Math Biosci Eng       Date:  2009-01       Impact factor: 2.080

10.  Systematic evaluation of validated type 2 diabetes and glycaemic trait loci for association with insulin clearance.

Authors:  M O Goodarzi; X Guo; J Cui; M R Jones; T Haritunians; A H Xiang; Y-D I Chen; K D Taylor; T A Buchanan; W A Hsueh; L J Raffel; J I Rotter
Journal:  Diabetologia       Date:  2013-03-14       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.